Luis Calzadilla Bertot - Search Results

Year	Number of Results
2009	1
2010	1
2011	2
2012	2
2013	3
2014	3
2015	2
2016	4
2017	1
2018	2
2019	2
2020	1
2021	4
2022	2
2023	1
2024	2

1

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Vilar-Gomez E, et al. Among authors: calzadilla bertot l. Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10. Gastroenterology. 2015. PMID: 25865049

2

Predicting liver-related events in NAFLD: A predictive model.

Calzadilla-Bertot L, Jeffrey GP, Wang Z, Huang Y, Garas G, Wallace M, de Boer B, George J, Eslam M, Phu A, Ampuero J, Lucena Valera A, Romero-Gómez M, Aller de la Fuente R, Adams LA. Calzadilla-Bertot L, et al. Hepatology. 2023 Oct 1;78(4):1240-1251. doi: 10.1097/HEP.0000000000000356. Epub 2023 Mar 31. Hepatology. 2023. PMID: 36994693

3

Reply.

Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Romero-Gomez M. Vilar-Gomez E, et al. Among authors: calzadilla bertot l. Hepatology. 2016 Dec;64(6):2266-2267. doi: 10.1002/hep.28670. Epub 2016 Jul 18. Hepatology. 2016. PMID: 27287070 No abstract available.

4

REPLY.

Calzadilla-Bertot L, Vilar-Gomez E, George J, Adams LA. Calzadilla-Bertot L, et al. Hepatology. 2021 Jul;74(1):531-532. doi: 10.1002/hep.31666. Epub 2021 Jun 15. Hepatology. 2021. PMID: 33277720 No abstract available.

5

Editorial: targeting liver biopsy in NAFLD - the need to expand non-invasive tools.

Calzadilla Bertot L. Calzadilla Bertot L. Aliment Pharmacol Ther. 2022 Jan;55(1):126-127. doi: 10.1111/apt.16705. Aliment Pharmacol Ther. 2022. PMID: 34907574 No abstract available.

6

The Natural Course of Non-Alcoholic Fatty Liver Disease.

Calzadilla Bertot L, Adams LA. Calzadilla Bertot L, et al. Int J Mol Sci. 2016 May 20;17(5):774. doi: 10.3390/ijms17050774. Int J Mol Sci. 2016. PMID: 27213358 Free PMC article. Review.

7

Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.

Bertot LC, Adams LA. Bertot LC, et al. Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791782 Review.

8

Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review.

Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K. Bertot LC, et al. Eur Radiol. 2011 Dec;21(12):2584-96. doi: 10.1007/s00330-011-2222-3. Epub 2011 Aug 20. Eur Radiol. 2011. PMID: 21858539 Review.

9

Editorial: Crystalising the burden of steatotic liver disease.

Bertot LC, Adams LA. Bertot LC, et al. Aliment Pharmacol Ther. 2024 May;59(10):1292-1293. doi: 10.1111/apt.17986. Aliment Pharmacol Ther. 2024. PMID: 38652765 No abstract available.

10

Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care.

Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Wang Z, et al. Among authors: bertot lc. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2041-2049.e5. doi: 10.1016/j.cgh.2021.09.040. Epub 2021 Oct 6. Clin Gastroenterol Hepatol. 2022. PMID: 34624564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

27 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year